Comparing Single-Dose Intravenous Dalbavancin to Standard 14-Day Antibiotic Treatment for Catheter-Related Bloodstream Infections Caused by Staphylococcus Aureus

What this Trial Is About

Researchers are evaluating treatments for catheter-related bloodstream infections CR-BSIs caused by Staphylococcus aureus, a common and serious hospital infection. This study aims to demonstrate that a single intravenous dose of dalbavancin is not less effective than the standard 14-day antibiotic treatment following catheter removal. The research also looks at cure rates at different times, mortality within 90 days, time to clear blood infection, patient quality of life, hospital stay length, costs, and adverse events. Participants will receive either a single 1500 mg intravenous dose of dalbavancin or the standard antibiotic therapy recommended by national guidelines for 14 days, which may include an oral switch after at least 7 days of intravenous treatment. Dalbavancins long half-life allows effective treatment with one dose, potentially reducing hospital stays and catheter-related complications. In case of clinical worsening, additional antibiotics may be prescribed as needed. During the study, patients will be closely monitored with blood cultures, assessments of infection clearance, quality of life questionnaires, and evaluations of hospital stay duration and healthcare costs. Adverse events will be tracked until 90 days after treatment. The main measure of success is the cure rate at 30 days. Participation includes follow-up visits up to 90 days to assess outcomes and safety, with total involvement lasting about three months.

Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus